Comparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study
Authors' conclusion
Among patients with gout, SGLT2is may reduce recurrent flares and gout-primary ED visits and hospitalizations and may provide cardiovascular benefits.
Study context
- Population
- Patients with gout and type 2 diabetes, general population database, 1 January 2014 to 30 June 2022
- Exposure
- SGLT2i initiation vs DPP-4i initiation
- Outcome
- Recurrent gout flare counts ascertained by emergency department (ED), hospitalization, outpatient, and medication dispensing records
Methodological detailsoverlap weighting (sensitivity analysis), Poisson and Cox proportional hazards regressions
- Overlap weighting (sensitivity analysis)
- Poisson and Cox proportional hazards regressions
Main finding
As reported in the abstract
Recurrent gout flare rate (events per 1000 person-years)
SGLT2i vs DPP-4iRelative risk (95% CI)
After propensity score matching
0.66(0.57–0.75)
SGLT2i vs DPP-4iRate difference, per 1000 person-years (95% CI)
Recurrent gout flare rate (events per 1000 person-years)
−27.4(−36.0 to −18.7)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Estimate | |
|---|---|---|
| Gout-primary ED visits and hospitalizationsSGLT2ivs DPP-4iPropensity score-matched | RR 0.52 (95% CI 0.32–0.84) | |
| Osteoarthritis encounter (negative control) | HR 1.07 (95% CI 0.95–1.20) | |
| 0.20.5125Ratio (log scale) |
| Outcome | RD (per 1000 person-years) (95% CI) | |
|---|---|---|
| Gout-primary ED visits and hospitalizationsSGLT2ivs DPP-4iPropensity score-matched | −3.4 (−5.8 to −0.9) | |
| −10−505Difference, per 1000 person-years (linear scale) |
Osteoarthritis encounter (negative control)
- No altered risk
Sensitivity analysis (propensity score overlap weighting)
- Results were similar when propensity score overlap weighting was applied
Safety
| Outcome | HR (CI) | |
|---|---|---|
| Genital infection (positive control) | 2.15 (1.39–3.30) | |
| 0.20.5125Hazard ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study. Ann Intern Med. Published 25 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →